Shanghai Haohai Biological Technology Co., Ltd. Class H (HK:6826)
:6826
Want to see HK:6826 full AI Analyst Report?
6826 Stock Chart & Stats
HK$24.90
-HK$0.40(-1.57%)
At close: 4:00 PM EST
HK$24.90
-HK$0.40(-1.57%)
Day’s Range― - ―
52-Week RangeHK$20.54 - HK$31.28
Previous CloseN/A
Volume220.22K
Average Volume (3M)211.55K
Market Cap
HK$8.85B
Enterprise ValueHK$4.81B
Total Cash (Recent Filing)HK$2.40B
Total Debt (Recent Filing)HK$416.01M
Price to Earnings (P/E)15.0
Beta0.78
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.28%
Share Statistics
EPS (TTM)0.98
Shares Outstanding35,929,040
10 Day Avg. Volume238,704
30 Day Avg. Volume211,551
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)0.94
Price to Sales (P/S)2.08
P/FCF Ratio11.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.66
Revenue Forecast (FY)HK$2.61B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageVery low debt levels materially limit financial risk and preserve flexibility. This conservatism supports sustained investment capacity for R&D, capacity and distribution, and provides resilience through industry cycles, reducing likelihood of forced financing or distress.
Broad Product Portfolio Across Ophthalmology And AestheticsA diversified product mix spanning intraocular lenses, eye-care consumables and hyaluronic-acid aesthetic products spreads revenue across clinical and aesthetic channels. This structural diversification supports recurring procedure-driven sales and cross-selling, lowering single-market dependency.
Positive Operating And Free Cash FlowSustained positive operating and free cash flow provides internal funding for product development, manufacturing and distribution expansion without heavy reliance on external funding. Positive cash generation underpins financial flexibility and supports durable operational planning.
Bears Say
Recent Revenue ContractionA material slowdown in top-line growth after prior expansion suggests waning demand or competitive pressure in core markets. Persistent or recurrent revenue declines would reduce headroom for reinvestment, hinder scale advantages, and constrain long-term growth potential.
Margin Compression And Weakening Operating ProfitSignificant margin erosion and a sharp drop in EBIT undermine profitability sustainability. Reduced margins weaken the company's ability to fund R&D, support marketing and maintain returns on equity, making earnings more vulnerable to cost inflation or pricing pressure.
Declining Cash Conversion And FCF Growth SlowdownFalling free cash flow growth and sub-1x coverage indicate earnings are not fully translating into cash. Persistently weak cash conversion can constrain capex, dividends and M&A, and may signal working-capital or collections pressure that impairs long-term financial flexibility.
Shanghai Haohai Biological Technology Co., Ltd. Class H News
6826 FAQ
What was Shanghai Haohai Biological Technology Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Haohai Biological Technology Co., Ltd. Class H lowest stock price was HK$20.54 and its highest was HK$31.28 in the past 12 months.
What is Shanghai Haohai Biological Technology Co., Ltd. Class H’s market cap?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s market cap is HK$8.85B.
When is Shanghai Haohai Biological Technology Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s upcoming earnings report date is Aug 21, 2026 which is in 92 days.
How were Shanghai Haohai Biological Technology Co., Ltd. Class H’s earnings last quarter?
Shanghai Haohai Biological Technology Co., Ltd. Class H released its earnings results on Apr 25, 2026. The company reported HK$0.367 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.367.
Is Shanghai Haohai Biological Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Haohai Biological Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Haohai Biological Technology Co., Ltd. Class H pay dividends?
Shanghai Haohai Biological Technology Co., Ltd. Class H pays a Quarterly dividend of HK$0.438 which represents an annual dividend yield of 4.28%. See more information on Shanghai Haohai Biological Technology Co., Ltd. Class H dividends here
What is Shanghai Haohai Biological Technology Co., Ltd. Class H’s EPS estimate?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Haohai Biological Technology Co., Ltd. Class H have?
Shanghai Haohai Biological Technology Co., Ltd. Class H has 35,929,040 shares outstanding.
What happened to Shanghai Haohai Biological Technology Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Haohai Biological Technology Co., Ltd. Class H reported an EPS of HK$0.367 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.726%.
Which hedge fund is a major shareholder of Shanghai Haohai Biological Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6826
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Haohai Biological Technology Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.53%
12-Months-Change
Fundamentals
Return on Equity
4.24%
Trailing 12-Months
Asset Growth
-1.06%
Trailing 12-Months
Company Description
Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, scalpels, etc.; orthopedics products, such as sodium hyaluronate injection and medical chitosan; wound repair products, including recombinant human epidermal growth factor for the treatment of burn wound, residual wound, donor site posttraumatic wound, and fresh or old wound of chronic ulcer; anti-adhesion materials comprising medical sodium hyaluronate gel and medical chitosan; and hemostatic materials, such as collagen sponge and porcine fibrin sealants. The company also provides medical aesthetics products comprising Matrifill, a first-generation HA dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; and radio frequency devices and laser equipment. In addition, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; and investment and trading business. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) Earnings & Revenues
Technical Analysis
Ascletis Pharma, Inc.
―
Lepu Biopharma Co. Ltd. Class H
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Options Prices
Currently, No data available
---